ES2162393T3 - Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica. - Google Patents

Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.

Info

Publication number
ES2162393T3
ES2162393T3 ES98306332T ES98306332T ES2162393T3 ES 2162393 T3 ES2162393 T3 ES 2162393T3 ES 98306332 T ES98306332 T ES 98306332T ES 98306332 T ES98306332 T ES 98306332T ES 2162393 T3 ES2162393 T3 ES 2162393T3
Authority
ES
Spain
Prior art keywords
alfa
infection
combination therapy
rna
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98306332T
Other languages
English (en)
Inventor
Janice K Albrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2162393(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/938,033 external-priority patent/US6172046B1/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2162393T3 publication Critical patent/ES2162393T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE EXPONE LA UTILIZACION DE RIBAVIRINA, INTERFERON ALFA O UNA COMBINACION DE RIBAVIRINA E INTERFERON ALFA, PARA LA FABRICACION DE UNA COMPOSICION FARMACEUTICA CON OBJETO DE TRATAR A UN PACIENTE CON UNA INFECCION CRONICA DE HEPATITIS C, Y ERRADICAR VCH-ARN DETECTABLE MEDIANTE UN PROCEDIMIENTO QUE CONSISTE EN ADMINISTRAR UNA CANTIDAD EFECTIVA DE RIBAVIRINA EN CONEXION CON UNA CANTIDAD EFECTIVA DE INTERFERON ALFA, EN DONDE EL PACIENTE ES UNO QUE NO HAYA RESPONDIDO A UN TRATAMIENTO PREVIO DE TERAPIA CON INTERFERON ALFA. LAS COMPOSICIONES PUEDEN UTILIZARSE EN UN PROCEDIMIENTO PARA TRATAR A UN PACIENTE CON INFECCION CRONICA DE HEPATITIS C Y ERRADICAR VCH-ARN DETECTABLE, SUPONIENDO UNA TERAPIA DE COMBINACION, UTILIZANDO UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE RIBAVIRINA Y UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE INTERFERON ALFA DURANTE UN PERIODO DE TIEMPO DESDE 20 HASTA 80 SEMANAS.
ES98306332T 1997-09-21 1998-08-07 Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica. Expired - Lifetime ES2162393T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/938,033 US6172046B1 (en) 1997-09-21 1997-09-21 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US93512397A 1997-09-22 1997-09-22

Publications (1)

Publication Number Publication Date
ES2162393T3 true ES2162393T3 (es) 2001-12-16

Family

ID=27130070

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01113628T Expired - Lifetime ES2186660T3 (es) 1997-09-21 1998-08-07 Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
ES98306332T Expired - Lifetime ES2162393T3 (es) 1997-09-21 1998-08-07 Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01113628T Expired - Lifetime ES2186660T3 (es) 1997-09-21 1998-08-07 Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.

Country Status (24)

Country Link
EP (3) EP0903148B1 (es)
JP (1) JPH11152231A (es)
KR (1) KR20010024188A (es)
CN (1) CN1250283C (es)
AR (1) AR013497A1 (es)
AT (2) ATE230999T1 (es)
AU (1) AU749924B2 (es)
BR (1) BR9812484A (es)
CA (1) CA2245938C (es)
CO (1) CO4970691A1 (es)
DE (2) DE69801970T2 (es)
DK (2) DK1136075T3 (es)
ES (2) ES2186660T3 (es)
HK (2) HK1016505A1 (es)
HU (1) HUP0100092A3 (es)
IL (1) IL134428A0 (es)
MY (1) MY117781A (es)
NO (1) NO20001437D0 (es)
NZ (1) NZ502740A (es)
PE (1) PE119199A1 (es)
PT (1) PT903148E (es)
SK (1) SK3922000A3 (es)
TW (1) TW568787B (es)
WO (1) WO1999015194A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5281726B2 (ja) * 1998-05-15 2013-09-04 メルク・シャープ・アンド・ドーム・コーポレーション 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法
WO2000037110A2 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
AU2156900A (en) * 1998-12-18 2000-07-12 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy
DE19919585A1 (de) 1999-04-29 2000-12-07 Cmi Ag Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
EP1278544A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7053228B2 (en) 2000-09-18 2006-05-30 Applied Research Systems Ars Holding N.V. Sulfur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
CN100348607C (zh) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒科病毒感染的2’和3’－核苷前药
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
JP2004155777A (ja) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Ｃ型慢性肝炎治療剤
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
NZ545159A (en) * 2003-08-13 2009-03-31 Smith Howard J & Ass Pty Ltd Method of treating viral infections
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2694440A1 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
EP0903148B1 (en) 2001-10-10
CO4970691A1 (es) 2000-11-07
MY117781A (en) 2004-08-30
WO1999015194A1 (en) 1999-04-01
HUP0100092A3 (en) 2002-03-28
JPH11152231A (ja) 1999-06-08
ATE230999T1 (de) 2003-02-15
EP1136075A1 (en) 2001-09-26
EP1317929A3 (en) 2003-07-02
AU9473798A (en) 1999-04-12
DE69801970D1 (de) 2001-11-15
HK1016505A1 (en) 1999-11-05
PT903148E (pt) 2002-02-28
ATE206618T1 (de) 2001-10-15
DK0903148T3 (da) 2001-12-17
CA2245938A1 (en) 1999-03-21
HUP0100092A2 (hu) 2001-05-28
DE69801970T2 (de) 2002-06-13
IL134428A0 (en) 2001-04-30
EP0903148A2 (en) 1999-03-24
NZ502740A (en) 2002-10-25
BR9812484A (pt) 2000-09-19
KR20010024188A (ko) 2001-03-26
ES2186660T3 (es) 2003-05-16
HK1041440B (zh) 2003-09-05
DE69810822T2 (de) 2003-11-20
CA2245938C (en) 2003-07-15
DE69810822D1 (de) 2003-02-20
CN1250283C (zh) 2006-04-12
EP1136075B1 (en) 2003-01-15
NO20001437L (no) 2000-03-20
DK1136075T3 (da) 2003-04-28
HK1041440A1 (en) 2002-07-12
TW568787B (en) 2004-01-01
SK3922000A3 (en) 2000-10-09
AU749924B2 (en) 2002-07-04
EP1317929A2 (en) 2003-06-11
AR013497A1 (es) 2000-12-27
CN1271292A (zh) 2000-10-25
EP0903148A3 (en) 1999-04-28
PE119199A1 (es) 1999-12-01
NO20001437D0 (no) 2000-03-20

Similar Documents

Publication Publication Date Title
ES2162393T3 (es) Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.
AR019551A1 (es) Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
MX9504415A (es) Eteres antivirales de isoesteres de sustrato de proteasa de aspartato.
MY164077A (en) Compositions and uses of et743 for treating cancer
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
DE60028559D1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
KR900701309A (ko) 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
AR013498A1 (es) Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa
BR0113115A (pt) Tratamento de hepatite c com timosina, interferon e ribavirina
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 903148

Country of ref document: ES